
Kite Pharma, Inc. pioneers in biomedical engineering, developing and manufacturing cancer immunotherapy products.
Kite Pharma, Inc., founded in 2009, is a biomedical engineering company with a core mission to develop innovative cancer immunotherapy products. The company's vision is to restore and enhance the patient's immune system to recognize and eradicate tumors effectively. Kite Pharma specializes in designing and manufacturing personalized cancer treatments, particularly focusing on chimeric antigen receptor (CAR) T-cell therapies. Their market focus is on providing advanced therapeutic solutions for patients with various types of cancer.
Notable figures associated with Kite Pharma include Arie Belldegrun, a renowned oncologist and the company's founder. The company has attracted significant investment from prominent venture capital firms and was acquired by Gilead Sciences in 2017 for $11.9 billion, highlighting its substantial impact and potential in the biopharmaceutical industry. Kite Pharma's key achievements include the FDA approval of Yescarta, a groundbreaking CAR T-cell therapy for certain types of lymphoma, marking a significant advancement in cancer treatment and solidifying its role as a leader in immunotherapy.

Seagen
seagen.com

Chimera Bioengineering
chimera.bio

Clovis Oncology

Nantkwest

Blueprint Medicines

Immpact Bio
immpact-bio.com

Allogene Therapeutics
allogene.com

Iovance Biotherapeutics
iovance.com

Immunome

Karyopharm Therapeutics
karyopharm.com

Duet BioTherapeutics

PharmaCyte Biotech
pharmacyte.com

Checkpoint Therapeutics
checkpointtx.com

Kestrel Therapeutics

Cel-Sci
cel-sci.com
Companies similar to Kite Pharma include Seagen, Chimera Bioengineering, Clovis Oncology and Nantkwest.
Kite Pharma was founded in 2009.
Kite Pharma's headquarters is located in Santa Monica, CA, US.
Kite Pharma's most recent funding round was for $250.1M (USD) in December 2015.
As of Dec 10, 2015, Kite Pharma has raised a total of $335.4M (USD).